T cell responses to recombinant isoforms, synthetic peptides and a mutant variant of Lep d 2, a major allergen from the dust mite Lepidoglyphus destructor.
BACKGROUND
The dust mite Lepidoglyphus destructor is an important cause of allergic reactions to dust, especially in farming environments. Two isoforms, recombinant (r)Lep d 2.01 and rLep d 2.02, of the major allergen Lep d 2, have previously been expressed as recombinant proteins. These isoforms differ 10.4% at the amino acid level. Furthermore, a mutant form of Lep d 2.01 (rLep d 2.6Cys) with a highly reduced IgE reactivity, has also been produced.


OBJECTIVE
To investigate the T cell responses to the recombinant isoforms of Lep d 2, the Lep d 2.6Cys mutant and peptides of Lep d 2, in allergic and non-allergic individuals.


METHODS
Peripheral blood mononuclear cells from 18 allergic and 16 non-allergic individuals were stimulated with the different antigens and the proliferative responses were measured. The cytokine production (interleukin (IL)-4, IL-5 and interferon (IFN)-gamma) were measured by ELISA.


RESULTS
Higher T cell proliferation was measured to isoform 01 than to 02 in 28/34 subjects. The responses to rLep d 2.6Cys were lower than to isoform 01 in most subjects, but higher than to Lep d 2.02. Two immuno-dominant peptides, corresponding to amino acid residue 11-25 and 61-75 were identified. The atopic subjects produced significantly lower IFN-gamma in response to Lep d 2.01 as compared to the non-atopics.


CONCLUSIONS
There was a significant difference in T cell response between the two isoforms of rLep d 2. The hypoallergenic mutant rLep d 2.6Cys was able to evoke a T cell response with a magnitude which is between the two isoforms. Amino acid residue 11-25 and 61-75 are the most frequently recognized parts of Lep d 2 and are likely to contain the immuno-dominant T cell epitopes.
Eriksson
T L
TL
Department of Medicine, Unit of Clinical Immunology & Allergy, Karolinska Hospital and Institutet, Stockholm, Sweden. tove.eriksson@ks.se
Gafvelin
G
G
Elfman
L H
LH
Johansson
C
C
Van Hage-Hamsten
M
M
Olsson
S
S
D000328:Adult; D000383:Agriculture; D000485:Allergens / Q000009:adverse effects* / Q000276:immunology; D000818:Animals; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology; D014644:Genetic Variation; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000097:blood / Q000276:immunology; D008875:Middle Aged; D008925:Mites / Q000276:immunology; D010455:Peptides / Q000009:adverse effects* / Q000276:immunology*; D020033:Protein Isoforms / Q000276:immunology; D011506:Proteins / Q000235:genetics*; D011994:Recombinant Proteins / Q000009:adverse effects* / Q000276:immunology*; D013548:Sweden / Q000453:epidemiology; D013601:T-Lymphocytes / Q000276:immunology*
D000485:Allergens; D016207:Cytokines; C090039:Lep d I allergen; D010455:Peptides; D020033:Protein Isoforms; D011506:Proteins; D011994:Recombinant Proteins